{"schema_version":"secwatch.filing_event.v1","accession":"0001654954-24-010758","form_type":"8-K","ticker":"VTAK","cik":"0001716621","company_name":"Catheter Precision, Inc.","filed_at":"2024-08-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.243617+00:00","generated_at":"2026-05-31T09:02:38.470897+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Catheter Precision Q2 revenue $93K, net loss $4.2M; cash only $16K at June 30","bullets":["Q2 revenue $93K, H1 $175K; net loss Q2 $4.2M, H1 $6.9M.","Cash at June 30 just $16K; rose to $330K by Aug 12 but remains extremely low.","First commercial LockeT sales in US: $38K in both Q2 and H1; 23 hospitals scheduling evaluations.","Total assets $26M, shareholders' equity $14.3M as of June 30.","14 new sales/clinical hires; VIVO evaluation started in Italy; VIVO EU Registry completed in June."],"urls":{"canonical":"https://secwatch.observer/filing/0001654954-24-010758","json":"https://secwatch.observer/filing/0001654954-24-010758.json","markdown":"https://secwatch.observer/filing/0001654954-24-010758.md","text":"https://secwatch.observer/filing/0001654954-24-010758.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424010758/0001654954-24-010758-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1716621/000165495424010758/vtak_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T09:02:38.470897+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}